RT Journal Article
SR Electronic
T1 Global lymphatic filariasis post-validation surveillance activities in 2024: A systematic review protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.14.24319037
DO 10.1101/2024.12.14.24319037
A1 Jian, Holly
A1 Lawford, Harriet
A1 McLure, Angus
A1 Lau, Colleen
A1 Craig, Adam
YR 2024
UL http://medrxiv.org/content/early/2024/12/16/2024.12.14.24319037.abstract
AB Introduction Lymphatic filariasis (LF) is a neglected tropical disease caused by infection with parasitic worms, spread by mosquitoes. In countries where LF is validated as eliminated as a public health problem by the World Health Organization (WHO), post-validation surveillance (PVS) is required to ensure recrudescence has not occurred and verify the sustained elimination of transmission. However, it is unclear what PVS strategies should be applied, how PVS strategies should be tailored to meet country capacity and need, and whether currently used approaches align with upcoming WHO guidelines.Objectives This study will aim to review available evidence on PVS implementation in countries previously endemic for LF; examine barriers and facilitators to PVS implementation; critique alignment in PVS activities with international guidelines; and identify knowledge gaps in PVS implementation that may be addressed through further research.Methods We will search four databases (PubMed, Scopus, Embase and Web of Science) for peer-reviewed literature and the WHO Institutional Repository for Information Sharing (IRIS) database for grey literature. Documents published between January 1, 2007 and November 5, 2024 will be included. Two reviewers will independently screen studies based on a priori inclusion and exclusion criteria. The quality of included studies will be assessed using the Joanna Briggs Institute Critical Appraisal Checklist, and deductive content analysis will be conducted to synthesise data. The study will also examine alignment with upcoming WHO PVS guidelines.Conclusion This review will systematically collate and analyse available literature on PVS of LF, which, to our knowledge, has not yet been conducted. Our study will synthesise knowledge in this field and provide an evidence base which may be used to guide the design of future PVS strategies.This protocol has been registered in PROSPERO (registration ID: CRD42024618436).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval is not required for this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.